Pyruvate Kinase Isoform M2 (PKM2) as a Possible Biomarker for Cancer

The recruitment status of this study is unknown because the information has not been verified recently.

Verified May 2010 by National University Hospital, Singapore.
Recruitment status was Recruiting

Sponsor:

Information provided by:

National University Hospital, Singapore

ClinicalTrials.gov Identifier:

NCT01130584

First received: May 24, 2010

Last updated: June 11, 2010

Last verified: May 2010

History of Changes

Purpose

The purpose of this study is to determine if pyruvate kinase M2 (PKM2) can be used as a biomarker in cancer.

Pyruvate kinase M2 is more elevated in malignant pleural fluid than in plasma, and may be a useful biomarker to distinguish between malignant and non-malignant causes of pleural effusion. In addition, pyruvate kinase M2 has also been found to be elevated in saliva in cancer patients compared to controls. Measuring pyruvate kinase M2 in saliva may be used to diagnose cancer or monitor the treatment progress of cancer.

Condition	Intervention
Cancer	Other: Pyruvate kinase isoform M2

Study Type:	Observational
Study Design:	Observational Model: Cohort Time Perspective: Prospective

Resource links provided by NLM:

MedlinePlus related topics: Cancer

Drug Information available for: Pyruvic acid

U.S. FDA Resources

Further study details as provided by National University Hospital, Singapore:

Study Start Date:

April 2010

Groups/Cohorts	Assigned Interventions
Cancer patient	Other: Pyruvate kinase isoform M2

Eligibility

Ages Eligible for Study:	21 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Probability Sample

Study Population

Any cancer patient

Criteria

Inclusion Criteria:

Any cancer patient with pleural effusion that is being drained through an indwelling chest-tube in an inpatient ward.

Exclusion Criteria:

Patient with a pleural effusion who does not have proven cancer or whose pleural effusion is not known to be malignant.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT01130584

Contacts

Contact: Soo Chin Lee, MBBS, MRCP

65 6772 4629

soo_chin_lee@nuhs.edu.sg

Locations

Singapore
National University Hospital, Singapore	Recruiting
Singapore, Singapore
Contact: Soo Chin Lee, MBBS, MRCP 65 6772 4629 soo_chin_lee@nuhs.edu.sg

Sponsors and Collaborators

National University Hospital, Singapore

More Information

Publications:

Elia S, Massoud R, Guggino G, Cristino B, Cortese C, De Massimi AR, Zenobi R. Tumor type M2-pyruvate-kinase levels in pleural fluid versus plasma in cancer patients: a further tool to define the need for invasive procedures. Eur J Cardiothorac Surg. 2008 Apr;33(4):723-7. Epub 2008 Feb 7.

Mazurek S. Pyruvate kinase type M2: a key regulator within the tumour metabolome and a tool for metabolic profiling of tumours. Ernst Schering Found Symp Proc. 2007;(4):99-124. Review.

ClinicalTrials.gov Identifier:	NCT01130584 History of Changes
Other Study ID Numbers:	PK01/02/10
Study First Received:	May 24, 2010
Last Updated:	June 11, 2010
Health Authority:	Singapore: Domain Specific Review Boards

Keywords provided by National University Hospital, Singapore:

Cancer Patients

ClinicalTrials.gov processed this record on May 22, 2013

To Top